JP2006503845A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006503845A5 JP2006503845A5 JP2004539056A JP2004539056A JP2006503845A5 JP 2006503845 A5 JP2006503845 A5 JP 2006503845A5 JP 2004539056 A JP2004539056 A JP 2004539056A JP 2004539056 A JP2004539056 A JP 2004539056A JP 2006503845 A5 JP2006503845 A5 JP 2006503845A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- hydrogen
- halo
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 Cc1c(C(N*)=O)c(*)cc(N(*)C2=CC=CCC2)n1 Chemical compound Cc1c(C(N*)=O)c(*)cc(N(*)C2=CC=CCC2)n1 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0222493.9A GB0222493D0 (en) | 2002-09-27 | 2002-09-27 | Compounds |
| PCT/EP2003/010930 WO2004029026A1 (en) | 2002-09-27 | 2003-09-25 | Pyridine derivatives as cb2 receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006503845A JP2006503845A (ja) | 2006-02-02 |
| JP2006503845A5 true JP2006503845A5 (https=) | 2006-05-18 |
Family
ID=9944904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004539056A Withdrawn JP2006503845A (ja) | 2002-09-27 | 2003-09-25 | Ｃｂ２受容体モジュレーターとしてのピリジン誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20060240048A1 (https=) |
| EP (1) | EP1565442B1 (https=) |
| JP (1) | JP2006503845A (https=) |
| KR (1) | KR20050071514A (https=) |
| CN (1) | CN1703402A (https=) |
| AR (1) | AR041395A1 (https=) |
| AT (1) | ATE378317T1 (https=) |
| AU (1) | AU2003268907A1 (https=) |
| BR (1) | BR0314635A (https=) |
| CA (1) | CA2500231A1 (https=) |
| DE (1) | DE60317555T2 (https=) |
| ES (1) | ES2294313T3 (https=) |
| GB (1) | GB0222493D0 (https=) |
| IS (1) | IS7809A (https=) |
| MA (1) | MA27448A1 (https=) |
| MX (1) | MXPA05003263A (https=) |
| NO (1) | NO20052028L (https=) |
| NZ (1) | NZ538943A (https=) |
| PL (1) | PL375990A1 (https=) |
| RU (1) | RU2005112752A (https=) |
| TW (1) | TW200413321A (https=) |
| WO (1) | WO2004029026A1 (https=) |
| ZA (1) | ZA200502084B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1492784A4 (en) | 2002-03-28 | 2006-03-29 | Merck & Co Inc | SUBSTITUTED 2,3-DIPHENYLPYRIDINES |
| UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| GB0402355D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| GB0402357D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| GB0402356D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| SE0401345D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine as scaffold |
| SE0401342D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
| SE0401343D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine N oxide as scaffold |
| KR20070034049A (ko) | 2004-06-09 | 2007-03-27 | 글락소 그룹 리미티드 | 피롤로피리딘 유도체 |
| WO2007017237A1 (en) * | 2005-08-09 | 2007-02-15 | Glaxo Group Limited | Imidazopyridine derivatives as cannabinoid receptor ligands |
| GB0519760D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
| US20090275611A1 (en) * | 2006-04-07 | 2009-11-05 | Boehringer Ingelheim International Gmbh | Compounds Which Modulate The CB2 Receptor |
| CN101522644B (zh) * | 2006-10-04 | 2013-04-24 | 霍夫曼-拉罗奇有限公司 | 作为cb2受体调节剂的吡嗪-2-羧酰胺衍生物 |
| WO2008063625A2 (en) * | 2006-11-20 | 2008-05-29 | Adolor Corporation | Pyridine compounds and methods of their use |
| MX2009009035A (es) * | 2007-02-22 | 2009-12-14 | Hemerus Medical Llc | Aparato de alta capacidad para filtracion de fluidos biologicos. |
| CA2747801A1 (en) * | 2009-01-22 | 2010-07-29 | Raqualia Pharma Inc. | N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity |
| AU2010231694A1 (en) | 2009-03-30 | 2011-10-06 | Astellas Pharma Inc. | Pyrimidine compound |
| NZ598891A (en) * | 2009-08-24 | 2014-05-30 | Neuralstem Inc | Synthesis of a neurostimulative piperazine |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| JP2013048962A (ja) * | 2012-12-12 | 2013-03-14 | Hemerus Medical Llc | 大容量の体液濾過装置 |
| WO2018055640A1 (en) * | 2016-09-22 | 2018-03-29 | Srf Limited | Process for the preparation of haloalkyl derivatives of nicotinic acid |
| CN112638430B (zh) | 2018-06-27 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 放射性标记的大麻素受体2配体 |
| CA3096777A1 (en) * | 2018-06-27 | 2020-02-02 | F. Hoffmann-La Roche Ag | Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| JP7478672B2 (ja) | 2018-06-27 | 2024-05-07 | エフ． ホフマン－ラ ロシュ アーゲー | カンナビノイド受容体２の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物 |
| WO2020025574A1 (en) | 2018-08-03 | 2020-02-06 | Bayer Aktiengesellschaft | Process for the preparation of 6-(haloalkyl)-2-halo-5-acylpyridines and intermediates for this process |
| EP3666759A1 (en) | 2018-12-10 | 2020-06-17 | Bayer Aktiengesellschaft | Preparation of 6-halo-2-(haloalkyl)-3-acylpyridines and intermediates therefor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112820A (en) * | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US7507767B2 (en) * | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
-
2002
- 2002-09-27 GB GBGB0222493.9A patent/GB0222493D0/en not_active Ceased
-
2003
- 2003-09-25 AR ARP030103499A patent/AR041395A1/es not_active Application Discontinuation
- 2003-09-25 JP JP2004539056A patent/JP2006503845A/ja not_active Withdrawn
- 2003-09-25 AU AU2003268907A patent/AU2003268907A1/en not_active Abandoned
- 2003-09-25 BR BR0314635-9A patent/BR0314635A/pt not_active IP Right Cessation
- 2003-09-25 PL PL03375990A patent/PL375990A1/xx not_active Application Discontinuation
- 2003-09-25 WO PCT/EP2003/010930 patent/WO2004029026A1/en not_active Ceased
- 2003-09-25 MX MXPA05003263A patent/MXPA05003263A/es unknown
- 2003-09-25 AT AT03750676T patent/ATE378317T1/de not_active IP Right Cessation
- 2003-09-25 ES ES03750676T patent/ES2294313T3/es not_active Expired - Lifetime
- 2003-09-25 CN CNA038254727A patent/CN1703402A/zh active Pending
- 2003-09-25 RU RU2005112752/04A patent/RU2005112752A/ru not_active Application Discontinuation
- 2003-09-25 KR KR1020057005234A patent/KR20050071514A/ko not_active Withdrawn
- 2003-09-25 NZ NZ538943A patent/NZ538943A/en unknown
- 2003-09-25 CA CA002500231A patent/CA2500231A1/en not_active Abandoned
- 2003-09-25 US US10/528,613 patent/US20060240048A1/en not_active Abandoned
- 2003-09-25 DE DE60317555T patent/DE60317555T2/de not_active Expired - Fee Related
- 2003-09-25 TW TW092126422A patent/TW200413321A/zh unknown
- 2003-09-25 EP EP03750676A patent/EP1565442B1/en not_active Expired - Lifetime
-
2005
- 2005-03-11 ZA ZA200502084A patent/ZA200502084B/en unknown
- 2005-03-28 MA MA28176A patent/MA27448A1/fr unknown
- 2005-04-19 IS IS7809A patent/IS7809A/is unknown
- 2005-04-26 NO NO20052028A patent/NO20052028L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006503845A5 (https=) | ||
| RU2435757C2 (ru) | Производные 3-циклил-2-(4-сульфамоилфенил)-n-циклилпропионамида, применимые для лечения нарушенной переносимости глюкозы и диабета | |
| RU2005112752A (ru) | Производные пиридина в качестве модуляторов рецептора сb2 | |
| JP2007538024A5 (https=) | ||
| AU688739B2 (en) | Method and composition for the treatment of Parkinson's disease | |
| RU2325389C2 (ru) | Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью | |
| JP2013531031A5 (https=) | ||
| JP2014037426A5 (https=) | ||
| US9381177B2 (en) | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations | |
| RU2001132632A (ru) | Производные пиперазина, применимые в качестве антагонистов CCR5 | |
| JP2007145875A5 (https=) | ||
| KR970704435A (ko) | 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands) | |
| JP2003012668A5 (https=) | ||
| JP2015504067A5 (https=) | ||
| JP2007519649A5 (https=) | ||
| JP2004529926A5 (https=) | ||
| JP2013510825A5 (https=) | ||
| JP2020532547A5 (https=) | ||
| JP2011521911A5 (https=) | ||
| JP2008539267A5 (https=) | ||
| JP2015524450A5 (https=) | ||
| JP2013520473A5 (https=) | ||
| RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов | |
| JP2013531070A5 (https=) | ||
| JP2004502670A5 (https=) |